Tissue Repair Advances Wound Trial as US Regulatory Filing Targets 2027
TRP: $0.095 +5.56% · MC: $6M
Tissue Repair reported approximately 112 patients randomised in its ongoing US Phase III chronic-wound trial and is targeting an FDA device application in April 2027, an alternative pathway it says could avoid the full Phase III recruitment plan. TR Pro+ is now available in all three Australian product formats, while the company ended the quarter with approximately $5 million in cash after receiving an R&D tax refund; underlying operating cash outflows were broadly in line with the prior quarter.

Comments